Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 6/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 3/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101699 | 1.00 | PTGES (0.48) | PTGESNPC1THRBATMESR1 | |
| SCHEMBL4097942 | 0.90 | PTGES (0.57) | PTGESBCL2MDM2MCL1 | |
| SCHEMBL4096225 | 0.81 | PTGES (0.54) | PTGESBCL2MDM2MCL1KDM4E | |
| SCHEMBL4086721 | 0.80 | PTGES (0.48) | PTGESBCL2MDM2MCL1 | |
| SCHEMBL4092676 | 0.79 | PTGES (0.47) | PTGESPTGDRBCL2MDM2MCL1 | |
| SCHEMBL4105667 | 0.77 | PTGES (0.48) | PTGESTHRBBCL2MDM2MCL1 | |
| SCHEMBL4086547 | 0.77 | MAPT (0.46) | PTGESNPC1KDM4E | |
| SCHEMBL4091286 | 0.76 | PTGES (0.44) | PTGESPTGDRBCL2MDM2MCL1 | |
| SCHEMBL1207346 | 0.74 | THRB (0.66) | NPC1THRBATMESR1GCK | |
| SCHEMBL1207345 | 0.74 | THRB (0.66) | NPC1THRBATMESR1GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | PTGES 3/4885NPC1 4849/4885THRB 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.